Researchers at the University of Maryland, Baltimore County (UMBC) have identified the enzyme USP15 as a promising molecular target for ovarian cancer therapy. Their study shows that ovarian cancer cells rely more heavily on USP15 than normal cells. Lowering USP15 levels slows tumor growth, disrupts chromosome separation during cell division, reduces the cancer’s ability to spread, and makes cells more sensitive to standard chemotherapy drugs. The findings, published in Molecular Therapy Oncology, open the door to more selective treatments that could reduce harm to healthy cells.